Preladenant, also known as SCH 420814, is a potent and selective antagonist at the adenosine A2A receptor, which was being researched as a potential treatment for Parkinson's disease. Positive results were reported in Phase II clinical trials in humans, but it did not prove itself to be more effective than a placebo during Phase III trials, and so was discontinued in May 2013.
Adenosine Receptor Related Products:
Reversine; SCH-58261; ZM241385; Istradefylline; Regadenoson; CGS-15943; Tozadenant; Adenosine amine congener (ADAC); CGS-21680; CGS-21680 HCl; Vipadenant